Enfortumab Vedotin-related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature.
Advanced urothelial cancer
African American
Bladder cancer
Cutaneous adverse events
Disease response
Enfortumab vedotin
Metastatic urothelial cancer
Skin toxicity
Upper tract urothelial cancer
Urothelial cancer
Journal
European urology open science
ISSN: 2666-1683
Titre abrégé: Eur Urol Open Sci
Pays: Netherlands
ID NLM: 101771568
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
accepted:
10
01
2023
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
24
2
2023
Statut:
epublish
Résumé
Enfortumab vedotin (EV) is an antibody-drug conjugate approved for the treatment of refractory advanced urothelial cancer. Cutaneous toxicity is well described but has not been correlated with response. In this retrospective single-center study, data from patients treated with more than one dose of EV between December 2017 and June 2022 were analyzed. Of 56 patients with a median age of 69 yr, 41 (73.2%) were male and 27 (48.2%) had any-grade skin toxicity. For all 51 patients evaluable by physician-assessed Response Evaluation Criteria in Solid Tumors (RECIST) criteria, the response rate was 41.2%. For those with cutaneous toxicity, the response rate was 57.7%; for those without cutaneous toxicity, it was 24.0% ( We evaluated patients with urothelial cancer who were treated at our institution with enfortumab vedotin (EV). We found that patients who experienced the common side effect of any type of skin toxicity, such as rash or itching, were more likely to have improvement in their cancer from EV treatment than those who did not experience skin toxicity. Patients with higher weight and body mass index when starting EV tended to have more skin toxicity. We conclude that presence of skin toxicity might help doctors make decisions about how to manage the care of patients with EV in the future.
Identifiants
pubmed: 36820243
doi: 10.1016/j.euros.2023.01.002
pii: S2666-1683(23)00002-2
pmc: PMC9937876
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100-103Informations de copyright
© 2023 The Authors.
Références
Oncologist. 2022 Mar 11;27(3):e223-e232
pubmed: 35274723
N Engl J Med. 2010 Nov 4;363(19):1812-21
pubmed: 21047225
J Clin Oncol. 2020 Apr 1;38(10):1041-1049
pubmed: 32031899
Nat Rev Urol. 2021 Feb;18(2):93-103
pubmed: 33239713
Lancet Oncol. 2021 Jun;22(6):872-882
pubmed: 33991512
Cancer Res. 2016 May 15;76(10):3003-13
pubmed: 27013195
J Clin Oncol. 2019 Oct 10;37(29):2592-2600
pubmed: 31356140
Invest New Drugs. 2020 Aug;38(4):1056-1066
pubmed: 31444589
N Engl J Med. 2021 Mar 25;384(12):1125-1135
pubmed: 33577729